RegenXBio ( (RGNX) ) has issued an announcement.
On March 4, 2025, REGENXBIO Inc. announced the closing of a strategic partnership with Nippon Shinyaku to develop and commercialize gene therapies RGX-121 and RGX-111 for Mucopolysaccharidosis II and I, respectively, in the United States and Asia. This collaboration is expected to enhance REGENXBIO’s ability to progress its programs, potentially leading to transformative treatments for patients with these rare diseases. RGX-121, anticipated to be the first gene therapy for MPS II, may receive FDA approval by late 2025, highlighting the partnership’s potential impact on the company’s operations and industry positioning.
More about RegenXBio
REGENXBIO Inc. is a leading clinical-stage biotechnology company focused on developing gene therapy treatments. Founded in 2009, the company has pioneered AAV Therapeutics, which are innovative gene therapy medicines aimed at treating retinal and rare diseases. Their pipeline includes treatments for conditions such as wet AMD, diabetic retinopathy, Duchenne muscular dystrophy, and MPS II. REGENXBIO’s therapies are designed to be one-time treatments with the potential to transform healthcare delivery.
YTD Price Performance: -16.41%
Average Trading Volume: 1,273,112
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $325.5M
See more insights into RGNX stock on TipRanks’ Stock Analysis page.